Clinical Trial

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V5. The secondary objectives of the study are to: * Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall and progression-free survival. * Assess pain control * Assess rate of surgical resection in Cohort 1.
Protocol Amendment History 1 change
notable Enrollment increased: 30 -> 40 participants 2026-05-07
Trial Details
NCT Number NCT06698458
Lead Sponsor Alpha Tau Medical LTD.
Conditions Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Enrollment 40 participants
Start Date 2025-06-17
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-16